Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19747747 | 0.94 | — | — | |
| SCHEMBL19745632 | 0.80 | — | — | |
| SCHEMBL19744807 | 0.75 | — | — | |
| SCHEMBL29399267 | 0.75 | GAA (0.35) | — | |
| SCHEMBL15859394 | 0.74 | — | — | |
| SCHEMBL15859395 | 0.74 | — | — | |
| SCHEMBL19744646 | 0.72 | ALDH1A1 (0.30) | ALDH1A1 | |
| SCHEMBL12070309 | 0.70 | GRIK1 (0.31) | — | |
| SCHEMBL29395889 | 0.69 | CA1 (0.34) | — | |
| SCHEMBL28583086 | 0.69 | MME (0.34) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11866422-B2 | Carbocyclic prolinamide derivatives | Orion Ophthalmology LLC (US) | 2024-01-09 | — | — | US | disclosed |
| US-20210347762-A1 | CARBOCYCLIC PROLINAMIDE DERIVATIVES | Orion Ophthalmology LLC (US) | 2021-11-11 | — | — | US | disclosed |
| US-11091465-B2 | — | — | 2021-08-17 | — | — | US | disclosed |
| US-20200385362-A1 | CARBOCYCLIC PROLINAMIDE DERIVATIVES | Orion Ophthalmology LLC (US) | 2020-12-10 | — | — | US | disclosed |
| US-20190202810-A1 | CARBOCYCLIC PROLINAMIDE DERIVATIVES | Orion Ophthalmology LLC (US) | 2019-07-04 | — | — | US | disclosed |
| EP-3472151-A1 | CARBOCYCLIC PROLINAMIDE DERIVATIVES | ORION OPTHALMOLOGY LLC (US) | 2019-04-24 | — | — | EP | disclosed |
| WO-2017222914-A1 | CARBOCYCLIC PROLINAMIDE DERIVATIVES | INCEPTION 4, INC. (US) | 2017-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190202810-A1 | CARBOCYCLIC PROLINAMIDE DERIVATIVES | HTRA1, ADCYAP1R1, HTRA2 | ALDH1A1 271/4885SMN1; SMN2 1713/4885 |
| US-20200385362-A1 | CARBOCYCLIC PROLINAMIDE DERIVATIVES | HTRA1, ADCYAP1R1, HTRA2 | ALDH1A1 271/4885SMN1; SMN2 1713/4885 |
| US-11866422-B2 | Carbocyclic prolinamide derivatives | HTRA1, ADCYAP1R1, HTRA2 | ALDH1A1 271/4885SMN1; SMN2 1713/4885 |
| US-11091465-B2 | — | HTRA1, ALDH1A2, ADCYAP1R1 | ALDH1A1 207/4885SMN1; SMN2 1654/4885 |
| US-20210347762-A1 | CARBOCYCLIC PROLINAMIDE DERIVATIVES | HTRA1, ADCYAP1R1, HTRA2 | ALDH1A1 271/4885SMN1; SMN2 1713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.